<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">810635</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2021.810635</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Gasdermin-E Mediated Pyroptosis&#x2014;A Novel Mechanism Regulating Migration, Invasion and Release of Inflammatory Cytokines in Rheumatoid Arthritis Fibroblast-like Synoviocytes</article-title>
<alt-title alt-title-type="left-running-head">Wu et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Gasdermin-E Mediated Pyroptosis in RA-FLS</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wu</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1541892/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xue-Pei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1259321/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Qian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zou</surname>
<given-names>Yao-Yao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Jian-Da</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Le-Feng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1560163/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zou</surname>
<given-names>Yao-Wei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1560564/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xue</surname>
<given-names>Ji-Meng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Ruo-Fan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zhong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dai</surname>
<given-names>Lie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/958887/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Rheumatology</institution>, <institution>Sun Yat-Sen Memorial Hospital</institution>, <institution>Sun Yat-Sen University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Orthopedic Surgery</institution>, <institution>Sun Yat-Sen Memorial Hospital</institution>, <institution>Sun Yat-Sen University</institution>, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/714901/overview">Nu Zhang</ext-link>, The University of Texas Health Science Center at San Antonio, United&#x20;States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/960966/overview">Carmen Conde</ext-link>, Instituto de Investigaci&#xf3;n Sanitaria, Spain</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/98964/overview">Jinhyun Kim</ext-link>, Chungnam National University, South Korea</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/385367/overview">Akio Morinobu</ext-link>, Kyoto University, Japan</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Lie Dai, <email>dailie@mail.sysu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Cell Death and Survival, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>810635</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>11</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>12</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Wu, Zhang, Zhang, Zou, Ma, Chen, Zou, Xue, Ma, Chen and Dai.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Wu, Zhang, Zhang, Zou, Ma, Chen, Zou, Xue, Ma, Chen and Dai</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Synovium fibroblast-like synoviocytes (FLSs) are important participants in the pathogenesis of synovitis and joint destruction in rheumatoid arthritis (RA). Pyroptosis is a pro-inflammatory and cell lytic programmed cell death mechanism mediated by gasdermin (GSDM) family proteins. In this study, we demonstrated the increased expression of GSDME and increased levels of GSDME-mediated pyroptosis in RA synovial tissues. <italic>In vitro</italic>, stimulation with TNF-&#x3b1; plus hypoxia mimicking the inflammatory and hypoxic environment in RA synovium induced GSDME-mediated pyroptosis in RA-FLSs in combination with the promotion of migration and invasion abilities and the release of inflammatory cytokines (IL-6, IL-8). Moreover, knockdown of GSDME significantly inhibited the proliferation rate, migration/invasion effects and cytokines released through the reduction of GSDME-mediated pyroptosis. The immunohistochemistry results showed that RA patients with high GSDME N-terminal (GSDME-NT) expression, which is the active form of GSDME, showed higher IL-6 expression in both lining and sublining layer of synovium than that in patients with low GSDME-NT expression, osteoarthritis and non-inflammatory orthopedic arthropathies. Our findings revealed a novel mechanism regulating cell proliferation, migration, invasion and inflammatory cytokines release during the process of GSDME mediated pyroptosis in&#x20;RA.</p>
</abstract>
<kwd-group>
<kwd>fibroblast-like synoviocytes</kwd>
<kwd>pyroptosis</kwd>
<kwd>gasdermin E</kwd>
<kwd>migration</kwd>
<kwd>invasion</kwd>
<kwd>inflammatory cytokines</kwd>
<kwd>rheumatoid arthritis</kwd>
</kwd-group>
<contract-num rid="cn001">82171780 81971527&#x20;81801605</contract-num>
<contract-num rid="cn002">2019A1515011928</contract-num>
<contract-num rid="cn003">2018A030313690</contract-num>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Basic and Applied Basic Research Foundation of Guangdong Province<named-content content-type="fundref-id">10.13039/501100021171</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Natural Science Foundation of Guangdong Province<named-content content-type="fundref-id">10.13039/501100003453</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovitis accompanied by excessive release of inflammatory cytokines and the destruction of bone and cartilage. Although the outcomes of RA patients have achieved considerable improvements due to treatments directed by &#x201c;Treat to Target&#x201d; strategy and other biological reagents, a significant proportion of patients fail to achieve clinical remission and experience radiographic joint damage progression (<xref ref-type="bibr" rid="B15">Lillegraven et&#x20;al., 2012</xref>). It is urgently needed to identify novel therapeutic targets for&#x20;RA.</p>
<p>Fibroblast-like synoviocytes (FLSs) located in the synovium have been identified as important contributors to the pathogenesis of RA due to their involvements in inflammation as well as cartilage and bone destruction (<xref ref-type="bibr" rid="B2">Bartok and Firestein, 2010</xref>). Increasing researches have been concentrated on the mechanisms underlying the abnormal proinflammatory responses and invasive behaviors of RA-FLSs and, hopefully, possible treatment strategies based on targeting RA-FLSs.</p>
<p>Pyroptosis is a form of programmed cell death featuring cell swelling and large bubbles blowing from the plasma membrane mediated by pore-forming gasdermin (GSDM) family proteins (<xref ref-type="bibr" rid="B24">Shi et&#x20;al., 2017</xref>). Gasdermin is a family of proteins sharing a functionally important gasdermin N domain with pore-forming activity (<xref ref-type="bibr" rid="B3">Chadha et&#x20;al., 2020</xref>). In the absence of activation signals, the gasdermin N domain and C domain are connected to each other and form an autoinhibitory structure (<xref ref-type="bibr" rid="B5">Ding et&#x20;al., 2016</xref>). After cleavage between the N domain and C domain by caspases, the two parts are separated, and the N domain is disinhibited (<xref ref-type="bibr" rid="B5">Ding et&#x20;al., 2016</xref>). The N terminal cleavages then bind to the cell membrane, oligomerize and form pores causing leakage of cell components, which is the pivotal and unique process of pyroptosis distinguished from other manners of cell death (<xref ref-type="bibr" rid="B5">Ding et&#x20;al., 2016</xref>). Essentially, pyroptosis is a pro-inflammatory process because of its cell lytic activity, which mediates excessive release of inflammatory mediators and thus induces and aggravates inflammation (<xref ref-type="bibr" rid="B24">Shi et&#x20;al., 2017</xref>). Based on this feature, pyroptosis might play a crucial role in the genesis and development of RA. A study has implicated the importance of GSDMD-mediated monocytes pyroptosis in RA pathology (<xref ref-type="bibr" rid="B28">Wu et&#x20;al., 2020</xref>), and Ze-Qing Zhai&#x2019;s latest article revealed a pathogenic role of GSDME in the pyroptosis of monocytes and macrophages in RA (<xref ref-type="bibr" rid="B30">Zhai et&#x20;al., 2021</xref>). However, the occurrence of pyroptosis as well as its mechanism and effect in RA-FLSs remain unknown. In this study, we illuminated the role of GSDME-mediated FLSs pyroptosis in RA, providing a novel insight for the mechanisms of inflammatory cytokines secretion and aggressive cell behaviors in RA-FLSs.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Material and Methods</title>
<sec id="s2-1">
<title>Reagent and Abs</title>
<p>Lipofectamine RNAiMAX reagent and opti-MEM medium were purchased from Thermo Fisher Scientific (United States). Small interfering RNAs (siRNAs) including GSDME (si-GSDME&#x23;1, stB0006132A; si-GSDME&#x23;2, stB0006132B; si-GSDME&#x23;3, stB0006132C) and control siRNAs (si-NC, siN0000001-1-10) were obtained from RiboBio (Guangzhou, China). The corresponding target sequences for GSDME silencing were si-GSDME&#x23;1, CCC&#x200b;ACT&#x200b;GCT&#x200b;TCT&#x200b;TTG&#x200b;TAT&#x200b;A; si-GSDME&#x23;2, CAA&#x200b;GCA&#x200b;GCT&#x200b;GTT&#x200b;TAT&#x200b;GAC&#x200b;A and si-GSDME&#x23;3, GGT&#x200b;CCT&#x200b;ATT&#x200b;TGA&#x200b;TGA&#x200b;TGA&#x200b;A. Primary antibodies including anti-human GSDME monoclonal ab (Abcam, ab215191), anti-human GSDME polyclonal ab (Proteintech, 13075-1-AP), anti-human-Thy1/CD90 ab (Abcam, ab181469), anti-human HIF-1&#x3b1; ab (Abcam, ab51608), anti-human Caspase-3 ab (Abcam, ab32351), anti-human IL-6 ab (Abcam ab9324) and anti-GAPDH ab (Cell Signaling Technology, &#x23;5174) were used in this study.</p>
</sec>
<sec id="s2-2">
<title>Preparation of Human Synovium Tissue</title>
<p>Active RA patients fulfilled the 2010 American College of Rheumatology (ACR) /European League against Rheumatism (EULAR) classification criteria (<xref ref-type="bibr" rid="B1">Aletaha et&#x20;al., 2010</xref>) and manifested with knee-joint swollen and pain were recruited from the Department of Rheumatology at Sun Yat-Sen Memorial Hospital between November 2020 and June 2021. RA synovium (<italic>n</italic>&#x20;&#x3d; 28) was obtained by Parker-Pearson needle biopsy. Control synovium was obtained from osteoarthritis (OA; <italic>n</italic>&#x20;&#x3d; 4), and non-inflammatory orthopedic arthropathies (Orth.A; <italic>n</italic>&#x20;&#x3d; 5) who received arthroplasty, or arthroscopy at the Department of Orthopedics as we previously described (<xref ref-type="bibr" rid="B17">Ma et&#x20;al., 2014</xref>). The clinical characteristics of included participants were listed in <xref ref-type="sec" rid="s11">Supplementary Table S1</xref>. The study was performed in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee of Sun Yat-Sen Memorial Hospital (SYSEC-2009-06 and SYSEC-KY-KS-012). All participants gave written informed consent.</p>
</sec>
<sec id="s2-3">
<title>FLSs Culture and Intervention</title>
<p>FLSs were isolated using modified tissue culture method (<xref ref-type="bibr" rid="B23">Schumacher and Kulka, 1972</xref>) and culture as we previously described (<xref ref-type="bibr" rid="B34">Zhou et&#x20;al., 2014</xref>). FLSs from passages 3 to 7 were used in this study. For TNF-&#x3b1; treatment, after serum starvation overnight, medium was replaced by serum-free DMEM containing recombinant TNF-&#x3b1; (R&#x26;D Systems, United&#x20;States) with the indicated concentration. For hypoxia treatment, cells were cultured in a humidified Tri-gas incubator (1% O<sub>2</sub>, 5% CO<sub>2</sub>, and 94% N<sub>2</sub>) for the indicated&#x20;time.</p>
</sec>
<sec id="s2-4">
<title>Knockdown of GSDME Transcripts</title>
<p>RA-FLSs (10 (<xref ref-type="bibr" rid="B5">Ding et&#x20;al., 2016</xref>) / well) were transfected with siRNAs(50&#xa0;nM, 24&#xa0;h)using Lipofectamine RNAiMAX reagent and Opti-MEM medium following the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2-5">
<title>Quantitative Real-Time PCR</title>
<p>Total RNA was prepared from cells using RNAiso Reagent (Takara, Japan). Complementary DNA (cDNA) samples were synthesized with reverse-transcription kit (Takara, Japan). Primers used for amplification of the cDNA were as follows (forward, reverse): GSDMA, 5&#x2032;-CTG&#x200b;ACA&#x200b;CCA&#x200b;CTT&#x200b;GAC&#x200b;AGC&#x200b;CT-3&#x2032; and 5&#x2032;-TTC&#x200b;AGG&#x200b;AAT&#x200b;GGG&#x200b;TGG&#x200b;TCT&#x200b;GC-3&#x2019;; GSDMB, 5&#x2032;-TCT&#x200b;CAG&#x200b;GGC&#x200b;CAT&#x200b;CTC&#x200b;AGC&#x200b;TA-3&#x2032; and 5&#x2032;-AGC&#x200b;ACC&#x200b;ATC&#x200b;CTT&#x200b;CTT&#x200b;CAT&#x200b;CGT-3; GSDMC, 5&#x2032;-GGA&#x200b;AGC&#x200b;AAA&#x200b;GAC&#x200b;CTG&#x200b;ACA&#x200b;CC-3&#x2032; and 5&#x2032;- GGA&#x200b;ACG&#x200b;GTC&#x200b;CTG&#x200b;TCA&#x200b;CAA&#x200b;CA-3; GSDMD, 5&#x2032;-CTG&#x200b;CTC&#x200b;CAT&#x200b;GAG&#x200b;AGG&#x200b;CAC&#x200b;C-3&#x2032; and 5&#x2032;-AGG&#x200b;ACG&#x200b;TCC&#x200b;AAG&#x200b;TCA&#x200b;GAG&#x200b;TCA-3; GSDME, 5&#x2032;-TGA&#x200b;TGG&#x200b;TGA&#x200b;CCT&#x200b;GAT&#x200b;TGC&#x200b;AG-3&#x2032; and 5&#x2032;- CGA&#x200b;CCA&#x200b;CTG&#x200b;GAC&#x200b;TCG&#x200b;GAA&#x200b;AT-3. qPCR was performed using QuantiTeckTM SYBR Green PCR kit (Takara, Japan). The reactions were initiated with denaturation of cDNA templates at 95&#xb0;C for 30&#xa0;s, 95&#xb0;C for 5&#xa0;s and 60&#xb0;C for 30&#xa0;s and amplification for 40 cycles on a Roche LightCycler480 sequence detector system (Roche, Switzerland).</p>
</sec>
<sec id="s2-6">
<title>EdU Proliferation Assay</title>
<p>The EdU staining was conducted using a BeyoClick EdU Cell Proliferation Assay Kit (Beyotime, China) according to the manufacturer&#x2019;s protocol. Images were captured using an Olympus IX73 microscope and the number of cells was manually counted.</p>
</sec>
<sec id="s2-7">
<title>Immunohistochemistry &#x26; Immunofluorescence Staining</title>
<p>IHC staining was carried out on the qualified synovium as we previously described (<xref ref-type="bibr" rid="B17">Ma et&#x20;al., 2014</xref>). Antigens were retrieved by boiling in EDTA (pH 9.0) for 3&#xa0;min at 120&#xb0;C in a pressure cooker. Sections were then washed, blocked, and incubated with rabbit anti-GSDME ab (Proteintech, 1:100) or mouse anti-IL-6 ab (Abcam, 1.5&#xa0;ug/ml) overnight at 4&#xb0;C. After washing, the sections were incubated with EnVision Mouse or Rabbit conjugate (Dako Corporation, United&#x20;States) for 30&#xa0;min at 37&#xb0;C. The color reaction was completed with the DAB-positive substrate and hematoxylin. Concentration-matched normal rabbit IgG (Cell Signaling Technology, &#x23;2729) and normal mouse IgG (Santa Cruz, sc-2025) were used as a negative control. The mean IL-6 expression in the synovium in each field was valuated under a 400&#xd7; optical microscope using the scoring system (<xref ref-type="bibr" rid="B8">Huang et&#x20;al., 2018</xref>) multiplied the intensity of the scoring (0, &#x3d; absent, 1&#x20;&#x3d; weak, 2&#x20;&#x3d; moderate, 3&#x20;&#x3d; strong) and the percentage of positive cells (0 &#x3d; 0%, 1&#x20;&#x3d; 1&#x2013;25%, 2&#x20;&#x3d; 26&#x2013;50%, 3&#x20;&#x3d; 51&#x2013;75%, 4&#x20;&#x3d; 76&#x2013;100%). The mean score from five different fields was determined as the finial IHC&#x20;score.</p>
<p>For IF staining, sections were incubated with rabbit anti-GSDME ab (Proteintech, 1:100) and mouse anti-CD90 Ab (Abcam, 1:100) overnight at 4&#xb0;C and then incubated with Alexa Fluor 594 conjugated anti-rabbit IgG (Cell Signaling Technology, &#x23;8889, 1:800) and Alexa Fluor 488 conjugated anti-mouse IgG (Cell Signaling Technology, &#x23;4408, 1:800) for 30&#xa0;min at 37&#xb0;C. After staining with DAPI slides were observed using a laser confocal microscope (LSM 510; Carl Zeiss, Germany).</p>
</sec>
<sec id="s2-8">
<title>Flow Cytometry Analysis for Cell Death</title>
<p>RA-FLSs (1.5 &#xd7; 10<sup>5</sup> / well) treated as indicated were collected and stained with Annexin V-FITC/propidium iodide (PI) Apoptosis Detection kit (Elabscience, China). Cell death analysis was performed on the BD FACS Caliber flow cytometer.</p>
</sec>
<sec id="s2-9">
<title>PI Staining and Microscopy Imaging</title>
<p>RA-FLSs were treated as indicated in 24-well plates and incubated with 1&#xa0;&#x3bc;g/ml PI (Solarbio, China) for 15&#xa0;min at 37&#xb0;C. Brightfield video and static brightfield / PI channel images of pyroptotic cells were captured using an Olympus IX73 microscope.</p>
</sec>
<sec id="s2-10">
<title>Lactate Dehydrogenase Assay</title>
<p>RA-FLSs (10 (<xref ref-type="bibr" rid="B3">Chadha et&#x20;al., 2020</xref>) /well) were seeded into 96-well culture plates and treated as indicated. The supernatant was collected and determined for LDH activity using LDH Assay Kit (Beyotime, China) according to the manufacturer&#x2019;s instruction.</p>
</sec>
<sec id="s2-11">
<title>Western Blot Analysis</title>
<p>RA-FLSs were collected and the total protein was extracted using Column Tissue &#x26; Cell Protein Extraction Kit (Epizyme, China) following the manufacturer&#x2019;s protocol. Concentrations of extracted protein were determined using the Pierce BCA assay kit (Thermo Fisher Scientific, United&#x20;States). Expression of proteins were analyzed using western blot as we previously described (<xref ref-type="bibr" rid="B18">Ma et&#x20;al., 2019a</xref>).</p>
</sec>
<sec id="s2-12">
<title>Cell Migration and Invasion Assays</title>
<sec id="s2-12-1">
<title>Wound Healing Assay</title>
<p>RA-FLSs (10 (<xref ref-type="bibr" rid="B5">Ding et&#x20;al., 2016</xref>)/well) were seeded in six-well plates and treated as indicated. Wound lines were made by scratching the cellular monolayer with sterile 200&#xa0;&#xb5;L pipette tips. After 48&#xa0;h of incubation in serum-free medium, cell migration was measured by calculating that healing area beyond reference line at 0&#xa0;h using ImageJ software.</p>
</sec>
<sec id="s2-12-2">
<title>Transwell Migration and Invasion Assay</title>
<p>Migration and invasion assay were performed using Transwell chambers as we described previously (<xref ref-type="bibr" rid="B16">Ma et&#x20;al., 2019b</xref>). For migration assay, 2&#x20;&#xd7; 10<sup>4</sup> RA-FLSs were resuspended by serum-free DMEM, placed in the upper chamber, and allowed to migrate for 12&#xa0;h. For invasion assay, the upper chamber was pre-coated with Matrigel (1:5) (BD Biosciences, United&#x20;States) and the same amount of FLSs were resuspended by serum-free DMEM, placed in the upper chamber allowed to invade for 24&#xa0;h. 10% FBS was placed in the lower chamber as a chemoattractant in both migration and invasion assay. After removal of cells remained on the upper surface of the membrane, the cells on the lower surface were stained with crystal violet staining solution (Solarbio, China) manually counted. Data were presented as the mean number of cells in five randomly captured 100&#xd7; fields.</p>
</sec>
</sec>
<sec id="s2-13">
<title>Cytokines Assays</title>
<p>Supernatants of cells with the indicated treatments were collected and centrifuged (12,000&#xa0;rpm, 5&#xa0;min), and secretion of cytokines was analyzed by a Protein Profiler Human Cytokine Array Kit (ARY005B, R&#x26;D Systems, United&#x20;States) following the manufacturer&#x2019;s protocol. Results were quantified using ImageJ software. Secretion levels of IL-6, IL-8 were also detected using corresponding ELISA kits (Neobioscience, China) following the manufacturer&#x2019;s protocol.</p>
</sec>
<sec id="s2-14">
<title>Statistical Analyses</title>
<p>Statistical analyses were performed on SPSS 25.0 statistical software (SPSS, United&#x20;States). Data were presented as mean&#x20;&#xb1; standard error of mean (s.e.m). Comparisons between two groups were analyzed by two-tailed Student&#x2019;s t&#x20;test. Multiple groups of samples were analyzed by one-way ANOVA, and pairwise comparisons were adjusted by the Bonferroni method. Differences were considered statistically significant with P values &#x3c;&#x20;0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>GSDME Expression in Synovium and FLSs</title>
<p>Using the data exploration website developed by Lewis, M. J., et&#x20;al. (<ext-link ext-link-type="uri" xlink:href="https://peac.hpc.qmul.ac.uk/">https://peac.hpc.qmul.ac.uk/</ext-link>) (<xref ref-type="bibr" rid="B14">Lewis et&#x20;al., 2019</xref>), GSDME (DFNA5) gene signatures were dissected across different synovial compartments in the Pathobiology of Early Arthritis Cohort (PEAC) and integrated with deep phenotypic profiling. GSDME expression was found in synovial tissue, and this gene was highly expressed in fibroid subtypes (<xref ref-type="sec" rid="s11">Supplementary Figure S1A</xref>). Furthermore, weighted correlation network analysis (WGCNA) showed that GSDME was annotated against THY-1(&#x2b;) fibroblast cell population (<xref ref-type="sec" rid="s11">Supplementary Figure S1B</xref>), which was found to be remarkably expanded in RA synovium compared to control synovium and correlated with severe and persistent inflammation in RA (<xref ref-type="bibr" rid="B4">Croft et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B27">Wei et&#x20;al., 2020</xref>).</p>
<p>To confirm the expression of GSDME in RA synovial tissue, 5 active RA patients with distinct knee joint pain were recruited, biopsied, and IHC staining was then conducted on these samples. GSDME full-length protein (GSDME-FL) expression was detected in both the lining and sublining layers (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). As the key step of pyroptosis, GSDME-FL is cut into an N-terminal fragment (GSDME-NT) with pore-forming activity and a C-terminal fragment by the activated cleaved caspase-3 and then cell pyroptosis is induced (<xref ref-type="bibr" rid="B5">Ding et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B26">Wang et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B9">Jiang et&#x20;al., 2020</xref>). To explore the existence of GSDME-mediated pyroptosis in synovium from RA patients and &#x201c;less inflamed&#x201d; disease controls, western blot analysis were performed for the detection of activated GSDME-NT in synovial tissue extracts from RA, OA, and Orth.A patients. As shown, GSDME-NT and GSDME-FL expression was significantly increased in synovium extracts from RA patients compared to those from Orth.A patients, but statistic difference was not found in either GSDME-FL or GSDME-NT levels between OA synovium and Orth.A synovium (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>, <xref ref-type="sec" rid="s11">Supplementary Figure S2</xref>). Immunofluorescence staining of RA and Orth.A synovium also revealed colocalization of GSDME with CD55 in the lining area and THY-1 FLSs in the sublining area, suggesting a link between FLSs and GSDME-mediated pyroptosis in RA synovium as detected above (<xref ref-type="fig" rid="F1">Figures 1C</xref>, <xref ref-type="sec" rid="s11">Supplementary Figure S3</xref>). Furthermore, in FLSs cultured <italic>in&#x20;vitro</italic>, GSDME mRNA, not GSDMA, GSDMB, GSDMC, or GSDMD, was the most abundantly transcribed, but no statistically significance was found between the mRNA levels of RA-FLSs and Orth. A-FLSs (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>). Protein levels of GSDME-FL and GSDME-NT were also detected by western blot. Results showed that GSDME-FL protein expression was increased in RA-FLSs compared to Orth.A-FLSs, but GSDME-NT expression showed no difference, possibly due to the absence of disease microenvironment <italic>in&#x20;vitro</italic> (<xref ref-type="fig" rid="F1">Figure&#x20;1E</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Expression of GSDME in synovium tissue and RA-FLSs. <bold>(A)</bold> Representative IHC staining of GSDME in synovium from RA patients (scale bar &#x3d; 200&#x20;/ 100&#xa0;&#x3bc;m). <bold>(B)</bold> Western blot of cleaved caspase-3, GSDME and N-terminal cleavage expression in lysate of synovium tissues from RA (<italic>n</italic>&#x20;&#x3d; 27), OA (<italic>n</italic>&#x20;&#x3d; 4) and Orth.A (<italic>n</italic>&#x20;&#x3d; 3) patients. <bold>(C)</bold> Representative immunofluorescence staining of GSDME (Gery), CD55 (Green), THY-1 (Red) and DAPI (Blue) in synovium of RA and Orth. A patients (scale bar &#x3d; 100&#xa0;&#x3bc;m). <bold>(D)</bold> GSDMA-E mRNA expression in FLSs from RA (<italic>n</italic>&#x20;&#x3d; 5) and Orth. A (<italic>n</italic>&#x20;&#x3d; 5) patients evaluated by qPCR. <bold>(E)</bold> GSDME-FL, GSDME-NT, caspase-3 and cleaved caspase-3 protein expression in FLSs from RA patients (<italic>n</italic>&#x20;&#x3d; 3) and Orth.A patients (<italic>n</italic>&#x20;&#x3d; 3) evaluated by western blot. Data are shown as mean&#x20;&#xb1; s.e.m. &#x2a;<italic>p</italic>&#x20;&#x3c;&#x20;0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 using one-way ANOVA.</p>
</caption>
<graphic xlink:href="fcell-09-810635-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Inflammatory and Hypoxic Microenvironment Triggers GSDME-Mediated RA-FLSs Pyroptosis</title>
<p>It has been well recognized that the inflammatory and hypoxic microenvironment in RA synovium facilitates the abnormal activation of RA FLSs. To mimic the microenvironment in RA synovium, RA-FLSs were treated with TNF-&#x3b1; and exposed to hypoxia (1% O<sub>2</sub>). The LDH release test (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>) showed that treatment with 40&#xa0;ng/ml TNF-&#x3b1; plus a 36-h hypoxia exposure represented the optimal trigger for lytic cell death of RA-FLSs and used in the subsequent experiments. The proportion of lytic cell death determined by flow cytometry analysis and microscopic PI staining was also significantly increased after treatment with TNF-&#x3b1; plus hypoxia (<xref ref-type="fig" rid="F2">Figures 2B,C</xref>). Moreover, characteristic swelling of cells, formation of large bubbles from plasma membrane, and eventually cell rupture of RA-FLSs were observed after treatment with TNF-&#x3b1; plus hypoxia, establishing the characteristic morphology of the pyroptosis process (<xref ref-type="fig" rid="F2">Figure&#x20;2E</xref>). Consistent with the abovementioned evidences, increased expression of GSDME-NT in RA FLSs treated with TNF-&#x3b1; plus hypoxia was detected by western blot (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>), further suggesting that TNF-&#x3b1; plus hypoxia triggers GSDME-mediated pyroptosis in RA-FLSs. Moreover, increases in HIF-1&#x3b1;, GSDME-FL and cleaved caspase-3 expression were also observed after TNF-&#x3b1; plus hypoxia treatment (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Inflammatory and hypoxic microenvironment triggers GSDME-mediated RA-FLSs pyroptosis. <bold>(A)</bold> LDH released by RA-FLSs treated with indicated concentrations of TNF-&#x3b1; under hypoxia conditions for 0-36&#xa0;h (<italic>n</italic>&#x20;&#x3d; 3). <bold>(B)</bold> Flow cytometry analysis (<italic>n</italic>&#x20;&#x3d; 3) of Propidium Iodide (PI) and Annexin V stained cells with or without TNF-&#x3b1; &#x2b; Hypoxia treatment (40&#xa0;ng/ml, 36&#xa0;h). <bold>(C)</bold> Representative phase-contrast images with PI staining by different treatment (scale bar &#x3d; 100&#xa0;&#x3bc;m). <bold>(D)</bold> Western blot analysis of caspase-3, cleaved caspase-3, GSDME and N-terminal cleavage of RA-FLSs treated with 40&#xa0;ng/ml TNF-&#x3b1; under hypoxia conditions for 0-48&#xa0;h (<italic>n</italic>&#x20;&#x3d; 6). HIF-1&#x3b1; serves as a marker of effective hypoxic stimulus, GADPH serves as a loading control. <bold>(E)</bold> Video captures of RA-FLSs under TNF-&#x3b1; &#x2b; Hypoxia treatment (40&#xa0;ng/ml, 36&#xa0;h). Blue arrow and yellow arrow point out two bursting cells. Yellow asterisks designate the swelling cells. Data are shown as mean&#x20;&#xb1; s.e.m and results are representative of three independent experiments. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001 using one-way ANOVA.</p>
</caption>
<graphic xlink:href="fcell-09-810635-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Downregulation of GSDME Alleviates TNF-&#x3b1; Plus Hypoxia-Induced RA-FLSs Pyroptosis</title>
<p>The silencing efficiency of GSDME siRNA was confirmed by qRT-PCR and western blot (<xref ref-type="sec" rid="s11">Supplementary Figures S3A,B</xref>). After TNF-&#x3b1; plus hypoxia treatment, the expression levels of HIF-1&#x3b1;, cleaved caspase-3, GSDME-FL and GSDME-NT were significantly increased (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>). However, the protein expression levels of GSDME-FL and GSDME-NT were decreased by GSDME siRNA transfection in both the control group and treatment group. Meanwhile, knockdown of GSDME lowered the rate of lytic cell death in both the control and treatment groups. (<xref ref-type="fig" rid="F3">Figures 3B,C</xref>). The results indicated that downregulation of GSDME mitigated RA FLSs pyroptosis induced by TNF-&#x3b1; plus hypoxia.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Suppression of RA-FLSs pyroptosis by downregulation of GSDME. <bold>(A)</bold> Western blot analysis of casepase-3, cleaved caspase-3, GSDME and HIF-1&#x3b1; of RA-FLSs treated with TNF-&#x3b1; &#x2b; hypoxia treatment (40&#xa0;ng/ml, 36&#xa0;h). GSDME siRNA or control siRNA was transfected for 24&#xa0;h before treatment (<italic>n</italic>&#x20;&#x3d; 6). GADPH serves as a loading control. <bold>(B)</bold> Flow cytometry analysis (<italic>n</italic>&#x20;&#x3d; 3) and <bold>(C)</bold> representative phase-contrast images with PI staining of RA-FLSs treated with or without TNF-&#x3b1; &#x2b; hypoxia (40&#xa0;ng/ml, 36&#xa0;h) after 24&#xa0;h of transfection with GSDME siRNA (si-GSDME) or control siRNA (si-NC). Data are shown as mean&#x20;&#xb1; s. e.m and results are representative of three independent experiments. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001 using one-way ANOVA.</p>
</caption>
<graphic xlink:href="fcell-09-810635-g003.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Suppression of RA-FLS Proliferation, Migration, and Invasion Through GSDME Knockdown</title>
<p>Excessive proliferation, abnormal migration and invasion are the basic pathologic characteristics of RA FLSs. Results of EDU assay showed that both TNF-&#x3b1;&#x2b;hypoxia treatment and GSDME knockdown restrained the proliferation of RA-FLSs (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>). On the other hand, silencing GSDME suppressed RA-FLSs migration and invasion abilities stimulated by TNF-&#x3b1;&#x2b;hypoxia treatment (<xref ref-type="fig" rid="F4">Figures 4B,C</xref>). Taken together, these results suggested a pivotal role of GSDME-mediated pyroptosis in the phenotypic transformation of RA&#x20;FLSs.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Suppression of proliferation, migration and invasion of RA-FLSs through inhibition of GSDME-mediated pyroptosis. <bold>(A)</bold> Decrease in RA-FLSs proliferation by knockdown of GSDME measured by EdU experiment (<italic>n</italic>&#x20;&#x3d; 6, scale bar &#x3d; 100&#xa0;&#x3bc;m). <bold>(B,C)</bold> Inhibition of RA-FLSs migration and invasion activities by GSDME knockdown. After 24&#xa0;h of transfection with GSDME siRNA (si-GSDME) or control siRNA (si-NC), RA-FLSs migration was determined by wound healing assay (B, <italic>n</italic>&#x20;&#x3d; 6, scale bar &#x3d; 200&#xa0;&#x3bc;m) and transwell chamber assay (C, <italic>n</italic>&#x20;&#x3d; 6, scale bar &#x3d; 100&#xa0;&#x3bc;m), invasion was determined for by matrigel-coated transwell assay (C, <italic>n</italic>&#x20;&#x3d; 6, scale bar &#x3d; 100&#xa0;&#x3bc;m). Data are shown as mean&#x20;&#xb1; s.e.m and results are representative of three independent experiments. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001 using one-way ANOVA.</p>
</caption>
<graphic xlink:href="fcell-09-810635-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Attenuation of Inflammatory Cytokines and Chemokines Release by Inhibition of GSDME-Mediated RA-FLSs Pyroptosis</title>
<p>Pyroptosis is characterized by cell rupture accompanied by release of a great quantity of cell components, including proinflammatory cytokines and chemokines, which are key regulators of cell behaviors in RA FLSs. To further investigate the underlying mechanisms, supernatants of RA FLSs after TNF-&#x3b1; plus hypoxia treatment were collected and detected by a Proteome Profiler Array Kit to identify the key cytokines and chemokine responding to GSDME knockdown. After TNF-&#x3b1;&#x2b;hypoxia stimulation, supernatant IL-6, IL-8 and CXCL1 level were remarkedly increased. Reversely, GSDME knockdown attenuated IL-6, IL-8 and CXCL1 release in response to TNF-&#x3b1; and hypoxia treatment. (<xref ref-type="fig" rid="F5">Figures 5A,B</xref>). The regulation of IL-6, IL-8 and release by GSDME knockdown was further validated by corresponding ELISA assay (<xref ref-type="fig" rid="F5">Figure&#x20;5C</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Alleviation of IL-6 and other inflammatory cytokines release by downregulation of GSDME-mediated RA-FLSs pyroptosis. <bold>(A,C)</bold> After siRNA transfection and TNF-&#x3b1; &#x2b; hypoxia treatment, cell culture supernatant was collected and the levels of cytokines and chemokines were measured using Proteome Profiler Human Cytokine Array Kit from R&#x26;D systems <bold>(A,B)</bold>. Supernatant levels of IL-6, IL-8 were further verified by ELISA (n &#x3d; 3) <bold>(C)</bold>. <bold>(D,E)</bold> HE and IHC staining for IL-6 of synovium tissues from RA (<italic>n</italic>&#x20;&#x3d; 21), OA (<italic>n</italic>&#x20;&#x3d; 4) and Orth.A (<italic>n</italic>&#x20;&#x3d; 5) patients (scale bar &#x3d; 100&#xa0;&#x3bc;m). RA synovium tissues were futher divide into low GSDME-NT level (<italic>n</italic>&#x20;&#x3d; 6) and high GSDME-NT level (<italic>n</italic>&#x20;&#x3d; 15) groups based on matched GSDME-NT level determined by western blotting. Data are shown as mean&#x20;&#xb1; s. e.m and results are representative of three independent experiments. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 using one-way ANOVA.</p>
</caption>
<graphic xlink:href="fcell-09-810635-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>Association Between GSDME-Mediated Pyroptosis and IL-6 Levels in RA Synovium</title>
<p>Based on the aforementioned results, suppression of GSDME-mediated RA-FLSs pyroptosis dramatically decreased the levels of IL-6 released <italic>in&#x20;vitro</italic>, implicating a novel mechanism by which IL-6 and other cytokines may be excessively released under inflammative and hypoxic circumstance such as RA. To verify this hypothesis in synovial samples, twenty-one RA, four OA and five Orth. A patients with qualified synovium were subjected to IHC analysis of the synovial IL-6 expression. IL-6 expression was observed in both the lining and sublining layers of the synovium (<xref ref-type="fig" rid="F5">Figure&#x20;5D</xref>). The median IHC scores of both lining and sublining IL-6 expression were significantly higher in RA patients than that in OA [Lining: 2.6 (1.2, 5.5) <italic>vs</italic>. 1.0 (0.9, 1.8), <italic>p</italic>&#x20;&#x3d; 0.049; Sublining: 2.2 (1.2, 2.6) <italic>vs</italic>. 0.7 (0.5, 1.0), <italic>p</italic>&#x20;&#x3d; 0.011], or Orth. A patients [Lining: 2.6 (1.2, 5.5) <italic>vs</italic>. 1.2 (0.7, 1.6), <italic>p</italic>&#x20;&#x3d; 0.037; Sublining: 2.2 (1.2, 2.6) <italic>vs</italic>. 1.0 (0.4, 1.7), <italic>p</italic>&#x20;&#x3d; 0.047]. RA patients were further classified into a high GSDME-NT expression group (<italic>n</italic>&#x20;&#x3d; 15) and a low GSDME-NT expression group (<italic>n</italic>&#x20;&#x3d; 6) according to the expression level of GSDME-NT in Orth.A determined by western blot analysis of synovial tissue extracts. Patients with expression levels greater than that noted in Orth.A were classified as high GSDME-NT expression; otherwise, patients were considered to have low GSDME-NT expression. RA patients with high GSDME-NT expression possess higher IL-6 IHC scores than those with low GSDME-NT expression [Lining: 2.8 (2.4, 5.6) <italic>vs</italic>. 1.1 (0.8, 3.4), <italic>p</italic>&#x20;&#x3d; 0.047; Sublining: 2.2 (1.4, 2.8) <italic>vs</italic>. 1.0 (0.8, 1.8), <italic>p</italic>&#x20;&#x3d; 0.029], suggesting that GSDME-mediated pyroptosis can obviously affect the synovial IL-6 level (<xref ref-type="fig" rid="F5">Figure&#x20;5E</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In the present study, for the first time, we reported the occurrence of GSDME-mediated pyroptosis in RA-FLSs under the inflammatory and hypoxic synovial microenvironments. Moreover, our results indicated that GSDME-mediated pyroptosis contributes to the proliferation, migration, invasion, and release of inflammatory cytokines in RA-FLSs, further providing a novel direction for RA pathology research and treatment development.</p>
<p>As a basic cell biological process, miscellaneous forms of cell death have been studied in RA-FLSs, and the most well-known is apoptosis&#x2014;a non-proinflammatory programmed cell death pattern. RA-FLSs are resistant to apoptosis and present with excessive proliferation and aggressive cell behaviors, including enhanced secretion of inflammatory and chemotactic cytokines and increased migrative and invasive ability. Induction of apoptosis in RA-FLSs through certain therapies is therapeutically beneficial in RA (<xref ref-type="bibr" rid="B21">Pope, 2002</xref>; <xref ref-type="bibr" rid="B25">Smith et&#x20;al., 2010</xref>). Differ from apoptosis, pyroptosis exhibits a pro-inflammatory peculiarity. Due to the formation of gasdermin pores on the plasma membrane, cells undergo osmolysis, and excessive cellular contents, including inflammatory cytokines and danger-associated molecular patterns (DAMPs), are released into extracellular compartment (<xref ref-type="bibr" rid="B24">Shi et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B3">Chadha et&#x20;al., 2020</xref>), thereby inducing and exaggerating inflammation. Pyroptosis has been implicated in cancer biology and infectious disease (<xref ref-type="bibr" rid="B26">Wang et&#x20;al., 2017</xref>; <xref ref-type="bibr" rid="B22">Sarhan et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B9">Jiang et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B12">Karki et&#x20;al., 2021</xref>). Moreover, several researches in osteoarthritis indicated that GSDMD-mediated FLSs pyroptosis participates in HIF-1&#x3b1;-induced synovial fibrosis in knee osteoarthritis (<xref ref-type="bibr" rid="B32">Zhao et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B31">Zhang et&#x20;al., 2019</xref>). A recent study also showed that GSDMD-mediated monocytes pyroptosis was involved in persistent inflammatory cytokine release in RA pathology (<xref ref-type="bibr" rid="B28">Wu et&#x20;al., 2020</xref>). The latest research ultimately studied the pathogenic role of GSDME in monocytes, macrophages and animal models of RA, suggesting that GSDME might be a potential therapeutic target for RA (<xref ref-type="bibr" rid="B30">Zhai et&#x20;al., 2021</xref>). However, involvement of GSDME-mediated pyroptosis in the function of RA-FLSs has not yet been reported.</p>
<p>Interestingly, we found that both full-length GSDME and GSDNE-N terminal cleavage was detected in RA-FLSs in synovial tissue <italic>in situ</italic> and cultured <italic>in&#x20;vitro</italic>, constituting the prerequisite of pyroptosis. In addition, by mimicking the particular microenvironment in which RA-FLSs are situated inflaming and hypoxic circumstances due to long-term and severe synovitis (<xref ref-type="bibr" rid="B6">Fearon et&#x20;al., 2016</xref>), we observed that a larger proportion of RA-FLSs undergo lytic cell death along with activated GSDME-NT expression and typical morphological features, strengthening the occurrence of GSDME-mediated RA FLSs pyroptosis in inflammatory and hypoxic microenvironments.</p>
<p>To study the roles of GSDME-mediated pyroptosis in RA-FLSs activation, we silenced GSDME expression with siRNA transfection and then determined the cell death rate, proliferation rate, migration and invasion ability, and inflammatory cytokines secretion of RA-FLSs. With GSDME suppression, the level of TNF-&#x3b1;&#x2b;hypoxia-induced pyroptosis was significantly downregulated, along with restrained cell proliferation rate, migration/invasion ability and secretion of cytokines (especially IL-6). These results indicated that GSDME-mediated pyroptosis may contribute to the overactivation and aggressive behavior of RA-FLSs, inflammatory mediators leakage into the extracellular space and inflammatory cell recruitment from blood to synovium, which are critical mechanisms of cartilage and bone erosion and persistent synovitis (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Illustration of a novel regulation of inflammatory cytokines secretion and aggressive cell behaviors in RA-FLSs through GSDME-mediated pyroptosis.</p>
</caption>
<graphic xlink:href="fcell-09-810635-g006.tif"/>
</fig>
<p>The pathogenic role of IL-6 in RA has been widely demonstrated. IL-6 is an important regulator of B-cell maturation, T&#x20;cell differentiation and bone homeostasis (<xref ref-type="bibr" rid="B19">McInnes and Schett, 2007</xref>; <xref ref-type="bibr" rid="B7">Garbers et&#x20;al., 2018</xref>). IL-6 increases the expression of receptor activator of nuclear factor-&#x3ba;B ligand (RANKL), an important factor for osteoclast differentiation, by osteoblasts, disturbing osteoclast&#x2013;osteoblast balance and exacerbating bone destruction (<xref ref-type="bibr" rid="B19">McInnes and Schett, 2007</xref>; <xref ref-type="bibr" rid="B7">Garbers et&#x20;al., 2018</xref>). Fibroblasts are major contributors to synovial inflammation and bone/cartilage destruction and are dominant producers of a variety of cytokines, especially IL-6 in RA, FLSs-derived IL-6 also regulates the production of matrix enzymes, such as matrix metalloproteins (MMPs), aggrecanases and cathepsins, aggravating articular damage (<xref ref-type="bibr" rid="B19">McInnes and Schett, 2007</xref>; <xref ref-type="bibr" rid="B20">Nguyen et&#x20;al., 2017</xref>). As a differentiation factor of TH17 cells, IL-6 is pivotal in local inflammation. Previous studies have shown that the high concentrations of IL-6 in synovial fluids positively correlate with disease activity and risk of radiographic progression in arthritis (<xref ref-type="bibr" rid="B19">McInnes and Schett, 2007</xref>; <xref ref-type="bibr" rid="B13">Larsson et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B20">Nguyen et&#x20;al., 2017</xref>). The application of IL-6-targeted therapy, such as tocilizumab, significantly reduces IL-6 expression in RA synovium, demonstrating improvements in RA therapy (<xref ref-type="bibr" rid="B10">Kanbe et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B11">Kang et&#x20;al., 2019</xref>). Nonetheless, understanding the mechanism of IL-6 (and probably other cytokines/chemokines) secretion by RA-FLSs through GSDME-mediated pyroptosis still provides a new perspective for developing more effective treatments in&#x20;RA.</p>
<p>Regrettably, most experiments in this study were conducted in RA-FLSs cultured <italic>in&#x20;vitro</italic>. Of note, the absolute level of pyroptosis induced by TNF-&#x3b1;&#x2b;hypoxia remained less than 10%, indicating that only a small fraction of RA-FLSs underwent pyroptosis. However, a single spark can start a prairie fire. Recent studies reported a mechanism of cytokines release in the sublytic phase before the truly membrane-lytic pyroptosis phase (<xref ref-type="bibr" rid="B29">Xia et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B33">Zhou and Abbott, 2021</xref>), which might explain the significant effects resulting from pyroptosis of a small number of cells. Due to the limitation of direct detection methods of GSDME-NT <italic>in situ</italic> in synovial tissue, the actual pyroptosis level of RA-FLSs <italic>in vivo</italic> still requires further verification. A more reliable and accurate method to detect pyroptosis levels in tissue and larger scale of samples and patient cohort data are required for correlation analysis between GSDME-mediated FLSs pyroptosis and clinical parameters in the future. Another limitation of this research is the lack of animal study. But thanks to Zhai&#x2019;s work, we can derive a key information from the CIA model of GSDME knockout mice that Gsdme<sup>&#x2212;/-</sup> mice exposed to collagen exhibited a reduced incidence of arthritis and lower clinical arthritis scores than wild-type mice, providing strong support of our results.</p>
<p>In conclusion, our study demonstrates a novel mechanism for modulating cell proliferation, migration, invasion and inflammatory cytokines secretion by GSDME mediated pyroptosis in RA-FLSs. These results provide new insight into the crosstalk between the inflammatory and hypoxic synovial microenvironment and the abnormally activated RA FLSs, thus suggesting a new direction for FLSs targeted therapy for&#x20;RA.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by Medical Ethics Committee of Sun Yat-Sen Memorial Hospital (SYSEC-2009-06 and SYSEC-KY-KS-012). The patients/participants provided their written informed consent to participate in this&#x20;study.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>All authors contributed to the final manuscript. TW, X-PZ, and QZ contributed equally to this work as participating in acquisition of synovium samples from needle biopsy, experiments planning and performing, statistical analysis, and drafting and revising this manuscript. LD, Y-YZ, J-DM helped design the study and critically revised the data and this manuscript. L-FC, Y-WZ, and J-MX helped with collection of the clinical materials and data analyzing. R-FM and ZC helped with collection and acquisition of surgical synovium samples and clinical data. All authors read and approved the final manuscript for publication.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>Grant support was provided by National Natural Science Foundation of China (grant No.82171780 to LD, 81971527 to LD, and 81801605 to Y-YZ), Basic and Applied Basic Research Foundation of Guangdong Province (No.2019A1515011928 to LD), Natural Science Foundation of Guangdong Province (No. 2018A030313690 to Y-YZ) and Science and Technology Program of Guangzhou (No.201904010088 to LD)</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, orclaim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>We gratefully thank all the patients and the members of the medical staff who generously collaborated with this research.</p>
</ack>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2021.810635/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2021.810635/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aletaha</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Neogi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Silman</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Funovits</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Felson</surname>
<given-names>D. T.</given-names>
</name>
<name>
<surname>Bingham</surname>
<given-names>C. O.</given-names>
<suffix>3rd</suffix>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology/European League against Rheumatism Collaborative Initiative</article-title>. <source>Arthritis Rheum.</source> <volume>62</volume>, <fpage>2569</fpage>&#x2013;<lpage>2581</lpage>. <pub-id pub-id-type="doi">10.1002/art.27584</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartok</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Firestein</surname>
<given-names>G. S.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Fibroblast-like Synoviocytes: Key Effector Cells in Rheumatoid Arthritis</article-title>. <source>Immunol. Rev.</source> <volume>233</volume>, <fpage>233</fpage>&#x2013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1111/j.0105-2896.2009.00859.x</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chadha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Behl</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bungau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arora</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Mechanistic Insights into the Role of Pyroptosis in Rheumatoid Arthritis</article-title>. <source>Curr. Res. Translational Med.</source> <volume>68</volume>, <fpage>151</fpage>&#x2013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1016/j.retram.2020.07.003</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croft</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Campos</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Attar</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Distinct Fibroblast Subsets Drive Inflammation and Damage in Arthritis</article-title>. <source>Nature</source> <volume>570</volume>, <fpage>246</fpage>&#x2013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-019-1263-7</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Pore-forming Activity and Structural Autoinhibition of the Gasdermin Family</article-title>. <source>Nature</source> <volume>535</volume>, <fpage>111</fpage>&#x2013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1038/nature18590</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fearon</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Canavan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biniecka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Veale</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Hypoxia, Mitochondrial Dysfunction and Synovial Invasiveness in Rheumatoid Arthritis</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>12</volume>, <fpage>385</fpage>&#x2013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2016.69</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garbers</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Heink</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Korn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rose-John</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Interleukin-6: Designing Specific Therapeutics for a Complex Cytokine</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>17</volume>, <fpage>395</fpage>&#x2013;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2018.45</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>17&#x3b2;-estradiol Upregulates IL6 Expression through the ER&#x3b2; Pathway to Promote Lung Adenocarcinoma Progression</article-title>. <source>J.&#x20;Exp. Clin. Cancer Res.</source> <volume>37</volume>, <fpage>133</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-018-0804-5</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The Caspase-3/GSDME Signal Pathway as a Switch between Apoptosis and Pyroptosis in Cancer</article-title>. <source>Cell Death Discov.</source> <volume>6</volume>, <fpage>112</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-020-00349-0</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanbe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hobo</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Inhibition of MAP Kinase in Synovium by Treatment with Tocilizumab in Rheumatoid Arthritis</article-title>. <source>Clin. Rheumatol.</source> <volume>30</volume>, <fpage>1407</fpage>&#x2013;<lpage>1413</lpage>. <pub-id pub-id-type="doi">10.1007/s10067-011-1833-z</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Narazaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Targeting Interleukin-6 Signaling in Clinic</article-title>. <source>Immunity</source> <volume>50</volume>, <fpage>1007</fpage>&#x2013;<lpage>1023</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.026</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Tuladhar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>E. P.</given-names>
</name>
<name>
<surname>Zalduondo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Samir</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Synergism of TNF-&#x3b1; and IFN-&#x3b3; Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes</article-title>. <source>Cell</source> <volume>184</volume>, <fpage>149</fpage>&#x2013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Englund</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Struglics</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lohmander</surname>
<given-names>L. S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Interleukin-6 and Tumor Necrosis Factor Alpha in Synovial Fluid Are Associated with Progression of Radiographic Knee Osteoarthritis in Subjects with Previous Meniscectomy</article-title>. <source>Osteoarthritis and Cartilage</source> <volume>23</volume>, <fpage>1906</fpage>&#x2013;<lpage>1914</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2015.05.035</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Blighe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Goldmann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hackney</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes</article-title>. <source>Cell Rep.</source> <volume>28</volume>, <fpage>2455</fpage>&#x2013;<lpage>2470</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.07.091</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lillegraven</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>F. H.</given-names>
</name>
<name>
<surname>Shadick</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Bykerk</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Frits</surname>
<given-names>M. L.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Remission and Radiographic Outcome in Rheumatoid Arthritis: Application of the 2011 ACR/EULAR Remission Criteria in an Observational Cohort</article-title>. <source>Ann. Rheum. Dis.</source> <volume>71</volume>, <fpage>681</fpage>&#x2013;<lpage>686</lpage>. <pub-id pub-id-type="doi">10.1136/ard.2011.154625</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.-D.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.-H.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y.-Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>A Novel Function of Artesunate on Inhibiting Migration and Invasion of Fibroblast-like Synoviocytes from Rheumatoid Arthritis Patients</article-title>. <source>Arthritis Res. Ther.</source> <volume>21</volume>, <fpage>153</fpage>. <pub-id pub-id-type="doi">10.1186/s13075-019-1935-6</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.-D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>D.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.-F.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y.-Q.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.-n.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Serum Matrix Metalloproteinase-3 as a Noninvasive Biomarker of Histological Synovitis for Diagnosis of Rheumatoid Arthritis</article-title>. <source>Mediators Inflamm.</source> <volume>2014</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2014/179284</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.&#x20;W.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y. Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q. H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.&#x20;Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Activation of the Peroxisome Proliferator-Activated Receptor &#x3b3; Coactivator 1&#x3b2;/NFATc1 Pathway in Circulating Osteoclast Precursors Associated with Bone Destruction in Rheumatoid Arthritis</article-title>. <source>Arthritis Rheumatol.</source> <volume>71</volume>, <fpage>1252</fpage>&#x2013;<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1002/art.40868</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McInnes</surname>
<given-names>I. B.</given-names>
</name>
<name>
<surname>Schett</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Cytokines in the Pathogenesis of Rheumatoid Arthritis</article-title>. <source>Nat. Rev. Immunol.</source> <volume>7</volume>, <fpage>429</fpage>&#x2013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1038/nri2094</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>H. N.</given-names>
</name>
<name>
<surname>Noss</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Huppertz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>G. F. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators</article-title>. <source>Immunity</source> <volume>46</volume>, <fpage>220</fpage>&#x2013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2017.01.004</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pope</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Apoptosis as a Therapeutic Tool in Rheumatoid Arthritis</article-title>. <source>Nat. Rev. Immunol.</source> <volume>2</volume>, <fpage>527</fpage>&#x2013;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1038/nri846</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarhan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Muendlein</surname>
<given-names>H. I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nilson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>A. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Caspase-8 Induces Cleavage of Gasdermin D to Elicit Pyroptosis duringYersiniainfection</article-title>. <source>Proc. Natl. Acad. Sci. USA</source> <volume>115</volume>, <fpage>E10888</fpage>&#x2013;<lpage>E10897</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1809548115</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schumacher</surname>
<given-names>H. R.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Kulka</surname>
<given-names>J.&#x20;P.</given-names>
</name>
</person-group> (<year>1972</year>). <article-title>Needle Biopsy of the Synovial Membrane - Experience with the Parker-Pearson Technic</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>286</volume>, <fpage>416</fpage>&#x2013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM197202242860807</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death</article-title>. <source>Trends Biochem. Sci.</source> <volume>42</volume>, <fpage>245</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.10.004</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Weedon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Papangelis</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roberts-Thomson</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Ahern</surname>
<given-names>M. J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Apoptosis in the Rheumatoid Arthritis Synovial Membrane: Modulation by Disease-Modifying Anti-rheumatic Drug Treatment</article-title>. <source>Rheumatology</source> <volume>49</volume>, <fpage>862</fpage>&#x2013;<lpage>875</lpage>. <pub-id pub-id-type="doi">10.1093/rheumatology/kep467</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Chemotherapy Drugs Induce Pyroptosis through Caspase-3 Cleavage of a Gasdermin</article-title>. <source>Nature</source> <volume>547</volume>, <fpage>99</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1038/nature22393</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Korsunsky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Korsunsky</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Watts</surname>
<given-names>G. F. M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Notch Signalling Drives Synovial Fibroblast Identity and Arthritis Pathology</article-title>. <source>Nature</source> <volume>582</volume>, <fpage>259</fpage>&#x2013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2222-z</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X.-y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.-t.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.-x.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.-d.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Complement C1q Synergizes with PTX3 in Promoting NLRP3 Inflammasome Over-activation and Pyroptosis in Rheumatoid Arthritis</article-title>. <source>J.&#x20;Autoimmun.</source> <volume>106</volume>, <fpage>102336</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaut.2019.102336</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Magupalli</surname>
<given-names>V. G.</given-names>
</name>
<name>
<surname>Pablo</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vora</surname>
<given-names>S. M.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Gasdermin D Pore Structure Reveals Preferential Release of Mature Interleukin-1</article-title>. <source>Nature</source> <volume>593</volume>, <fpage>607</fpage>&#x2013;<lpage>611</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03478-3</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Attenuation of Rheumatoid Arthritis through the Inhibition of caspase3/GSDME&#x2010;mediated Pyroptosis Induced by TNF&#x2010;&#x3b1;</article-title>. <source>Arthritis Rheumatol.</source> <volume>4</volume>. <pub-id pub-id-type="doi">10.1002/art.41963</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Increased HIF-1&#x3b1; in Knee Osteoarthritis Aggravate Synovial Fibrosis via Fibroblast-like Synoviocyte Pyroptosis</article-title>. <source>Oxidative Med. Cell Longevity</source> <volume>2019</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1155/2019/6326517</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>L. R.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>NLRP1 and NLRP3 Inflammasomes Mediate LPS/ATP-induced P-yroptosis in K-nee O-steoarthritis</article-title>. <source>Mol. Med. Rep.</source> <volume>17</volume>, <fpage>5463</fpage>&#x2013;<lpage>5469</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2018.8520</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>D. W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Gasdermin E Permits Interleukin-1 Beta Release in Distinct Sublytic and Pyroptotic Phases</article-title>. <source>Cell Rep.</source> <volume>35</volume>, <fpage>108998</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2021.108998</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.-D.</given-names>
</name>
<name>
<surname>Mo</surname>
<given-names>Y.-Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>D.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.-F.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.-N.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Down-regulating Peroxisome Proliferator-Activated Receptor-Gamma Coactivator-1beta Alleviates the Proinflammatory Effect of Rheumatoid Arthritis Fibroblast-like Synoviocytes through Inhibiting Extracellular Signal-Regulated Kinase, P38 and Nuclear Factor-kappaB Activation</article-title>. <source>Arthritis Res. Ther.</source> <volume>16</volume>, <fpage>472</fpage>. <pub-id pub-id-type="doi">10.1186/s13075-014-0472-6</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>